Trial Profile
A Randomized, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Interaction After Single Ascending Oral Doses of AZD1656 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Oct 2012
Price :
$35
*
At a glance
- Drugs AZD 1656 (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 04 Sep 2012 Results published in the International Journal of Clinical Pharmacology and Therapeutics.
- 01 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Oct 2008 Status changed from recruiting to active, no longer recruiting, according to clinicaltrials.gov.